Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6916462 | 0.83 | GBA1 (0.43) | TMEM97SIGMAR1GBA1ACEPOLB | |
| SCHEMBL8998 | 0.74 | FAAH (0.43) | GBA1ACEFAAHPOLB | |
| SCHEMBL28090 | 0.73 | POLB (0.44) | GBA1FAAHPOLB | |
| SCHEMBL450052 | 0.73 | GBA1 (0.42) | GBA1FAAHPOLB | |
| SCHEMBL317332 | 0.72 | TAAR1 (0.38) | GBA1ACEPOLBNPC1RAB9A | |
| SCHEMBL4644559 | 0.71 | MMP2 (0.33) | TMEM97SIGMAR1ACE | |
| SCHEMBL20842916 | 0.71 | GBA1 (0.50) | TMEM97SIGMAR1GBA1ALDH1A1 | |
| SCHEMBL9185438 | 0.70 | GBA1 (0.34) | TMEM97SIGMAR1GBA1ACEFAAH | |
| SCHEMBL694287 | 0.70 | MAOB (0.48) | GBA1POLB | |
| SCHEMBL22206478 | 0.69 | GBA1 (0.44) | TMEM97SIGMAR1GBA1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1847 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952652-B | Imaging element, stacked imaging element, imaging device, and electronic device | 索尼公司 | 2023-09-19 | — | — | CN | claimed |
| EP-3245198-B1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2020-03-11 | — | — | EP | claimed |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | claimed |
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-12-28 | — | — | US | claimed |
| EP-3245198-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | Novartis AG (CH) | 2017-11-22 | — | — | EP | claimed |
| WO-2016113668-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | NOVARTIS AG (CH) | 2016-07-21 | — | — | WO | claimed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | claimed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | claimed |
| US-6036888-A | ADDING SULFUR-CONTAINING HETEROCYCLIC RING COMPOUNDS TO AQUEOUS ALKANOLAMINE SOLUTION TO INHIBIT CORROSION OF METALS IN ACID GAS RICH AND ACID GAS LEAN PORTIONS OF AN ACID GAS REMOVAL UNIT | BETZDEARBORN INC. (US) | 2000-03-14 | — | — | US | claimed |
| WO-1999010561-A1 | CORROSION INHIBITOR FOR ALKANOLAMINE UNITS | BETZDEARBORN INC. (US) | 1999-03-04 | — | — | WO | claimed |
| EP-0790983-A1 | PESTICIDAL PYRIDINE THIOAMIDES | Novartis AG (CH) | 1997-08-27 | — | — | EP | claimed |
| WO-1996014301-A1 | PESTICIDAL PYRIDINE THIOAMIDES | NOVARTIS AG (CH) | 1996-05-17 | — | — | WO | claimed |
| US-5403936-A | Irradiating organic optical material comprising oxazoline derivative with light | KABUSHIKI KAISHA TOSHIBA (JP) | 1995-04-04 | — | — | US | claimed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-5332648-A | Alklali soluble phenolic polymer, cyclic ester or sulfonate which converts to the acid, an onium salt which generates an an acid on exposure to radiation | KABUSHIKI KAISHA TOSHIBA (JP) | 1994-07-26 | — | — | US | disclosed |
| EP-0422900-B1 | Organic nonlinear optical material and nonlinear optical element | TOSHIBA KK (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-5279921-A | Pattern formation resist and pattern formation method | KABUSHIKI KAISHA TOSHIBA (JP) | 1994-01-18 | — | — | US | disclosed |
| EP-0422900-A2 | Organic nonlinear optical material and nonlinear optical element | KABUSHIKI KAISHA TOSHIBA (JP) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369473-A1 | PYRROLIDINE DERIVATIVES AS ANGIOTENSIN II TYPE 2 ANTAGONISTS | AGTR2, AGTR1, AVPR2 | TMEM97 2725/4885SIGMAR1 1124/4885GBA1 4732/4885 |
| US-10065943-B2 | Pyrrolidine derivatives as angiotensin II type 2 antagonists | AGTR2, AGTR1, ACE2 | TMEM97 2217/4885SIGMAR1 759/4885GBA1 4568/4885 |
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | TMEM97 511/4885SIGMAR1 59/4885GBA1 2136/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | TMEM97 1266/4885SIGMAR1 1317/4885GBA1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.